Document Detail

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
MedLine Citation:
PMID:  21881937     Owner:  NLM     Status:  Publisher    
Clinical trials suggest that increased risk of osteoporosis and fracture are the only serious side effects of adjuvant aromatase inhibitors (AIs), but little is known regarding toxicities of AIs in non-trial populations. We evaluated whether use of AIs was associated with myocardial infarction, stroke, and fracture in a community-based population. Using data from the HealthCore Integrated Research Database, 44,463 women aged ≥50 years with ≥2 breast cancer diagnosis codes between 2001 and 2007 were followed through 2008. Of these, 44,026 were matched using propensity score methods to women aged ≥50 years with no breast cancer codes. We assessed whether treatment with AIs was associated with myocardial infarction, stroke, and fracture using Cox proportional hazards models with time-varying treatment variables. Among breast cancer patients, 68.7% received no hormonal therapy, 20.6% received AIs (15.8% received only AIs, 4.8% were also treated with tamoxifen), and 10.7% received tamoxifen only. Breast cancer patients on AIs had a higher risk of any fracture (AHR = 1.13, 95% CI = 1.02-1.25) than breast cancer patients not receiving hormonal therapy. Patients on tamoxifen had a lower risk of hip fracture (AHR = 0.51, 95% CI = 0.32-0.81) than breast cancer patients not receiving hormonal therapy. Rates of myocardial infarction and stroke for patients on AIs or tamoxifen did not differ significantly from breast cancer patients not on therapy. The side effect profile of AIs in this community-based population was similar to that seen in clinical trials. These findings provide reassurance that AIs appear to be associated with few serious side effects.
Jennifer A Ligibel; A James O'Malley; Maxine Fisher; Gregory W Daniel; Eric P Winer; Nancy L Keating
Related Documents :
23122537 - Expression of underglycosylated muc1 antigen in cancerous and adjacent normal breast ti...
8538197 - Rationale for the use of genistein-containing soy matrices in chemoprevention trials fo...
11060797 - Potential use of lipoxygenase inhibitors for cancer chemoprevention.
21652577 - Prospective transgeicam study of the impact of the 21-gene recurrence score assay and t...
2541197 - Liver cell dysplasia accompanying hepatocellular carcinoma in southern africa. differen...
12941847 - Identification of a novel inhibitor of breast cell growth that is down-regulated by est...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-9-1
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  -     ISSN:  1573-7217     ISO Abbreviation:  -     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-9-1     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Rocky Mountain spotted fever: 'starry sky' appearance with diffusion-weighted imaging in a child.
Next Document:  Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast ...